Sab Biotherapeutics (SABS) closed at $3.11 on November 11, 2026, up 1.3% from the previous close, on volume of 758,402 shares (30-day average 615,177).
Data as of November 11, 2026.
SAB BIO to Participate in Upcoming Investor Conferences
Globe Newswire (Mon, 9-Nov 8:30 AM ET)
SAB Biotherapeutics Advances SAFEGUARD Enrollment, Supporting Buy Rating and $11 Price Target
TipRanks (Fri, 6-Nov 9:30 AM ET)
SAB Biotherapeutics (SABS) Gets a Buy from Guggenheim
TipRanks (Fri, 6-Nov 9:24 AM ET)
Barclays Reaffirms Their Buy Rating on SAB Biotherapeutics (SABS)
TipRanks (Fri, 6-Nov 4:07 AM ET)
SAB BIO Reports Q3 2026 Financial Results and Provides Business Highlights
Globe Newswire (Thu, 5-Nov 7:30 AM ET)
Globe Newswire (Thu, 29-Oct 8:30 AM ET)
SAB BIO to Participate in Chardan 10th Annual Healthcare Conference
Globe Newswire (Wed, 14-Oct 8:30 AM ET)
SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes
Globe Newswire (Tue, 13-Oct 8:30 AM ET)
SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress
Globe Newswire (Thu, 1-Oct 8:30 AM ET)
Globe Newswire (Tue, 22-Sep 8:30 AM ET)
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
Sab Biotherapeutics trades on the NASDAQ stock market under the symbol SABS.
As of November 11, 2026, SABS stock price climbed to $3.11 with 758,402 million shares trading.
SABS has a beta of 0.86, meaning it tends to be less sensitive to market movements. SABS has a correlation of 0.03 to the broad based SPY ETF.
SABS has a market cap of $280.18 million. This is considered a Small Cap stock.
In the last 3 years, SABS traded as high as $9.72 and as low as $1.00.
The top ETF exchange traded funds that SABS belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.
SABS has underperformed the market in the last year with a return of -2.8%, while the SPY ETF gained +12.6%. In the last 3 month period, SABS fell short of the market, returning -17.7%, while SPY returned -1.5%. However, in the most recent 2 weeks SABS has outperformed the stock market by returning +1.3%, while SPY returned -1.3%.
SABS support price is $2.91 and resistance is $3.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SABS shares will trade within this expected range on the day.
